Sex-specific signals in Alzheimer’s blood biomarkers
A recent study in Alzheimer’s & Dementia investigates sex differences in key plasma biomarkers for Alzheimer’s disease, including amyloid beta (Aβ)42/40 ratio, phosphorylated tau (p-tau)217, and glial fibrillary acidic protein (GFAP). The research, using data from the Alzheimer’s Disease Neuroimaging Initiative, found distinct biomarker profiles between men and women across cognitively unimpaired and impaired groups. While overall diagnostic performance for amyloid positivity was similar, the specificity and predictive value of certain biomarkers like p-tau217 varied by sex. Notably, p-tau217 and its ratio to Aβ42 were predictive of future cognitive decline only in cognitively unimpaired women, highlighting a sex-specific prognostic utility.
Why it might matter to you: For pathologists and molecular diagnosticians, this research underscores that biological sex is a critical variable in interpreting blood-based biomarker results for neurodegenerative disease. It suggests that while universal cutoffs may be functional, the clinical meaning and prognostic value of a biomarker level can differ significantly between men and women. This has direct implications for refining diagnostic algorithms, improving the accuracy of trial participant enrichment, and personalizing risk assessments in clinical practice.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
